SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma - Quaterly Results

10 Aug 2022 Evaluate
The sales figure stood at Rs. 1309.88 millions for the June 2022 quarter. The mentioned figure indicates a growth of about 37.11% as compared to Rs. 955.37 millions during the year-ago period.The Net Loss for the quarter ended June 2022 is Rs. -140.88 millions as compared to Net Loss of Rs. -234.18 millions of corresponding quarter ended June 2021Operating Profit saw a handsome growth to 153.81 millions from 75.69 millions in the quarter ended June 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 1309.88 955.37 37.11 1309.88 955.37 37.11 5569.74 4506.95 23.58
Other Income 29.31 31.23 -6.15 29.31 31.23 -6.15 90.03 64.61 39.34
PBIDT 153.81 75.69 103.21 153.81 75.69 103.21 662.62 643.62 2.95
Interest 78.40 108.79 -27.93 78.40 108.79 -27.93 320.12 513.36 -37.64
PBDT 75.41 -33.10 -327.82 75.41 -33.10 -327.82 342.50 130.26 162.94
Depreciation 216.29 201.08 7.56 216.29 201.08 7.56 870.21 1088.99 -20.09
PBT -140.88 -234.18 -39.84 -140.88 -234.18 -39.84 -527.71 -958.73 -44.96
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -140.88 -234.18 -39.84 -140.88 -234.18 -39.84 -527.71 -958.73 -44.96
Equity 408.16 408.16 0.00 408.16 408.16 0.00 408.16 408.16 0.00
PBIDTM(%) 11.74 7.92 48.21 11.74 7.92 48.21 11.90 14.28 -16.69

Orchid Pharma Share Price

547.60 -22.90 (-4.01%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×